Overview 

You may have seen creatine on store shelves, often marketed as a must-have supplement for bodybuilders and weightlifters. While it's true that creatine supplements support muscle growth, creatine is also naturally produced in the body, and this metabolite plays a critical role in brain and muscle development, as it helps regenerate and store energy for quick cellular use.¹

Cerebral Creatine Deficiency Syndromes (CCDSs) are a group of rare congenital disorders in which the body is unable to synthesise or transport creatine properly. A shortage of creatine during early childhood can affect normal brain development, potentially causing intellectual disabilities, developmental delays, speech impairments, and seizures.² Long-term creatine supplementation is the standard treatment, and early detection and intervention can greatly improve outcomes.³ Prompt treatment depends on early detection, which often uses tools like Magnetic Resonance Spectroscopy (MRS).²

In this article, you will learn how MRS helps detect CCDS, how it can differentiate between types of CCDS, and how it can continue to empower patients throughout the treatment process. 

What are cerebral creatine deficiency syndromes (CCDSs)?

CCDSs are a group of very rare inherited disorders characterised by creatine deficiency in the brain. In the early stages of neurodevelopment, not having enough creatine can delay brain maturation, which can result in cognitive, motor, and behavioural issues.⁴ 

Symptoms

Common symptoms of CCDS include: 

• Intellectual disability
• Developmental delays
• Speech-language disorder (69% of patients)
• Movement disorders, such as a wide-based gait or ataxia 
• Epilepsy
• Behavioural disorders such as ADHD or autism (75% of patients)

The first signs of CCDS become evident in the first months of a baby's life, but sometimes the diagnosis doesn't happen until years later.²

Key types of CCDS

Your body makes creatine through a series of reactions happening mainly in the liver, kidneys, and pancreas. The process of making the creatine involves two main steps completed by two enzymes. Another protein then transports the creatine directly into the cells. 

CCDS is what happens when, due to a genetic mutation, some of the proteins needed in this process don't function properly. Based on which protein is malfunctioning, CCDSs can be classified into three types:⁵

• Guanidinoacetate methyltransferase (GAMT) deficiency 
• L-arginine: glycine amidinotransferase (AGAT) deficiency 
• Creatine transporter (CRTR) deficiency

AGAT deficiency

AGAT is the enzyme that produces the intermediate compound needed to make creatine. AGAT deficiency is the rarest type of CCDS, with only 16 reported cases. Compared to the other types, AGAT deficiency patients are less likely to experience behaviour problems or seizures.²

GAMT deficiency

GAMT is the enzyme that produces creatine from AGAT's product.¹ There are 130 cases of reported GAMT deficiency. Patients with this type of CCDS are less likely to experience muscle-related issues like muscle weakness or movement disorders.²

Creatine transporter (CRTR) deficiency

When there is a CRTR deficiency, AGAT and GAMT successfully synthesise creatine, but, because CRTR can't transport it, the brain cells can't access it. Without CRTR, the produced creatine can't enter the brain from your bloodstream, nor can it enter the cells to give them energy. This syndrome type is estimated to affect 0.4-2% of all males with intellectual disabilities and presents with more muscle-associated symptoms like hypotonia.² 

What is brain magnetic resonance spectroscopy (MRS)?

How MRS differs from a regular MRI

You might not have heard of MRS, but you might be somewhat familiar with Magnetic Resonance Imaging (MRI), its more popular sibling. The two work under the same principles, and, as MRS becomes more widely used, they're even becoming part of the same instruments. 

Both MRS and MRI exploit the magnetic properties of the molecules in your organs to gather information on their chemical makeup. They record the reaction of the atoms to electromagnetic fields, which gives information on the molecules' composition and location.⁷

MRI and MRS can work together to provide a complete picture of your brain's health. MRI gives spatial information to create a detailed map of an organ's structure. On the other hand, MRS measures and quantifies the chemical composition of those same organs.⁸ In the brain, MRS can measure the presence of chemicals essential for brain function, like creatine.⁷

Is it safe?

MRS, like MRI, is a relatively safe imaging tool. Unlike computed tomography and radiography, it uses non-ionising radiation. There are still risks associated with the strong magnet used in the machine. When the magnet turns on, metal objects like piercings or jewellery will start moving rapidly and with force, potentially causing injuries.

Before undergoing an MRS scan, be sure to alert the technician of any implants or metallic foreign bodies, as they might be affected by the magnetic field and even harm you.⁹

How MRS helps diagnose CCDS

What MRS can reveal

Location of the deficiency

Creatine deficiency diagnosis involves many tests, including genetic testing and urine analysis.² However, creatine is everywhere in the body, and, without MRS, there is no way to make sure that the lack of creatine is concentrated in the brain, a characteristic aspect of CCDS diagnosis.¹⁰

Extent of the deficiency

In MRS, each type of molecule produces a unique signal. Creatine, along with other metabolites, has a strong signal in MRS.⁷ The strength of these signals is compared to the expected values from healthy individuals. This comparison shows how severe the deficiency is.⁸ Thanks to MRS, neurologists can compare your creatine levels to normal creatine levels, which can help guide treatment plans.

Distinguishing types of CCDS

MRS can detect levels of other molecules that are also relevant to CCDS diagnosis. The presence of these chemicals determines whether a patient has GAMT, AGAT, or CRTR deficiency. 

Depending on the type of deficiency, different compounds will start accumulating to abnormal levels:⁶

• GAMT deficiency results in high levels of guanidinoacetate and low levels of creatine in the brain
• AGAT deficiency results in low levels of creatine in both the brain and muscles, with no guanidinoacetate
• CRTR deficiency results in low levels of creatine in the brain and normal creatine levels in the muscles 

MRS can accurately measure the levels of both guanidinoacetate and creatine,⁸ helping narrow down the diagnosis to the type of deficiency.^11,8 

MRS can also detect metabolites in other organs, including skeletal muscles, where creatine is most abundant.¹² As studies suggest that only AGAT and GAMT deficiencies affect muscle creatine levels, MRS can be a valuable tool in ruling out CRTR deficiency.⁶

It's important to note that, because of the rarity of CCDS and the limited amount of research studies, there is no standard diagnostic process, and this process does not always include MRS. Although MRS is an effective screening method, correct diagnoses usually require the collaboration of several healthcare specialists and the use of different but complementary tools.^2,6

How it fits into the diagnostic process

MRS is only one part of the diagnostic toolkit for CCDS. Suspected cases of CCDS are investigated using a combination of: 

• Genetic testing 
• Biochemical analysis (urine, plasma, cerebrospinal fluid)
• MRS
• Patient assessment
• Investigation into family history

MRS plays an essential role in this picture, as it can pinpoint the affected location of the creatine deficiency: for CCDS patients, this is the brain. 

MRS also detects creatine deficiencies that other tests may miss. In some patients, especially those with a partial deficiency, urine and blood tests may appear completely normal. However, their brains may still lack creatine. Because MRS looks directly at brain chemistry, it can detect these subtle deficiencies. MRS's high sensitivity opens the door to diagnosis and potential treatment for individuals who might otherwise go undiagnosed.²

Why early use of MRS matters

Early diagnosis can be life-changing for a young CCDS patient. A quick diagnosis leads to early intervention, which positively impacts brain development. For some CCDS patients, early diagnosis has meant an opportunity for a life with milder symptoms and slower disease progression.^2,3 MRS can speed up the diagnostic process, confirming results from biochemical analysis and identifying the location of the deficiency. 

Treatment and outlook

Available treatments

Treating the deficiency 

The first line of treatment for CCDS is high-dose creatine supplements; however, the effectiveness of the treatment often depends on the type of deficiency at play. AGAT and GMAT deficiency patients show the most significant improvement with creatine supplementation.^3,10 However, the effectiveness of creatine supplements is less certain in CRTR patients.²

Treating the symptoms

Mitigating the individual symptoms of CCDS is often just as important as treating the creatine deficiency itself, and doing so usually requires interdisciplinary collaboration. CCDS symptoms affect behaviour, development, movement, and neurology, often requiring multiple specialists.² Your treatment plan will be personalised and adapted to your symptomatic footprint to provide you with the best outcome possible.

MRS and treatment monitoring 

Brain MRS has been used to monitor patients' response to creatine supplementation for children with GAMT deficiency. While this can help ensure that the brain is starting to absorb creatine, it does not necessarily imply improvement in symptoms.¹⁰ 

Summary

Cerebral Creatine Deficiency Syndromes (CCDSs) are a group of rare genetic conditions that can impact a child's brain development by limiting the brain's access to creatine, an essential chemical for energy. While CCDS symptoms, like developmental delays or seizures, may appear in the first months of life, they can be hard to link to CCDS without the right tools. That's where Magnetic Resonance Spectroscopy (MRS) becomes so important. Unlike other diagnostic methods, MRS looks directly at brain chemistry, catching creatine deficiencies directly in the organs that might be affected. 

If you or someone you love is facing a potential CCDS diagnosis, MRS could be a key step toward understanding what's happening inside the brain. It doesn't replace other tests, but it adds powerful insight, especially when distinguishing between types of CCDS.

Early detection can make a difference. For many families, catching CCDS early has meant significantly improved long-term outcomes. MRS can also help monitor how your child's brain responds to treatment over time.